A model to predict survival in patients with end-stage liver disease

Patrick Sequeira Kamath, R. H. Wiesner, M. Malinchoc, Walter K Kremers, Terry M Therneau, C. L. Kosberg, G. D'Amico, E. R. Dickson, W. R. Kim

Research output: Contribution to journalArticle

2982 Citations (Scopus)

Abstract

A recent mandate emphasizes severity of liver disease to determine priorities in allocating organs for liver transplantation and necessitates a disease severity index based on generalizable, verifiable, and easily obtained variables. The aim of the study was to examine the generalizability of a model previously created to estimate survival of patients undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure in patient groups with a broader range of disease severity and etiology. The Model for End-Stage Liver Disease (MELD) consists of serum bilirubin and creatinine levels, International Normalized Ratio (INR) for prothrombin time, and etiology of liver disease. The model's validity was tested in 4 independent data sets, including (1) patients hospitalized for hepatic decompensation (referred to as "hospitalized" patients), (2) ambulatory patients with noncholestatic cirrhosis, (3) patients with primary biliary cirrhosis (PBC), and (4) unselected patients from the 1980s with cirrhosis (referred to as "historical" patients). In these patients, the model's ability to classify patients according to their risk of death was examined using the concordance (c)-statistic. The MELD scale performed well in predicting death within 3 months with a c-statistic of (1) 0.87 for hospitalized patients, (2) 0.80 for noncholestatic ambulatory patients, (3) 0.87 for PBC patients, and (4) 0.78 for historical cirrhotic patients. Individual complications of portal hypertension had minimal impact on the model's prediction (range of improvement in c-statistic: <.01 for spontaneous bacterial peritonitis and variceal hemorrhage to ascites: 0.01-0.03). The MELD scale is a reliable measure of mortality risk in patients with end-stage liver disease and suitable for use as a disease severity index to determine organ allocation priorities.

Original languageEnglish (US)
Pages (from-to)464-470
Number of pages7
JournalHepatology
Volume33
Issue number2
DOIs
StatePublished - 2001

Fingerprint

End Stage Liver Disease
Survival
Liver Diseases
Fibrosis
Transjugular Intrahepatic Portasystemic Shunt
International Normalized Ratio
Biliary Liver Cirrhosis
Prothrombin Time
Portal Hypertension
Organ Transplantation
Peritonitis
Bilirubin
Ascites
Liver Transplantation

ASJC Scopus subject areas

  • Hepatology

Cite this

A model to predict survival in patients with end-stage liver disease. / Kamath, Patrick Sequeira; Wiesner, R. H.; Malinchoc, M.; Kremers, Walter K; Therneau, Terry M; Kosberg, C. L.; D'Amico, G.; Dickson, E. R.; Kim, W. R.

In: Hepatology, Vol. 33, No. 2, 2001, p. 464-470.

Research output: Contribution to journalArticle

Kamath, PS, Wiesner, RH, Malinchoc, M, Kremers, WK, Therneau, TM, Kosberg, CL, D'Amico, G, Dickson, ER & Kim, WR 2001, 'A model to predict survival in patients with end-stage liver disease', Hepatology, vol. 33, no. 2, pp. 464-470. https://doi.org/10.1053/jhep.2001.22172
Kamath, Patrick Sequeira ; Wiesner, R. H. ; Malinchoc, M. ; Kremers, Walter K ; Therneau, Terry M ; Kosberg, C. L. ; D'Amico, G. ; Dickson, E. R. ; Kim, W. R. / A model to predict survival in patients with end-stage liver disease. In: Hepatology. 2001 ; Vol. 33, No. 2. pp. 464-470.
@article{5ddd6ff84cae4ca58218565546fe1361,
title = "A model to predict survival in patients with end-stage liver disease",
abstract = "A recent mandate emphasizes severity of liver disease to determine priorities in allocating organs for liver transplantation and necessitates a disease severity index based on generalizable, verifiable, and easily obtained variables. The aim of the study was to examine the generalizability of a model previously created to estimate survival of patients undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure in patient groups with a broader range of disease severity and etiology. The Model for End-Stage Liver Disease (MELD) consists of serum bilirubin and creatinine levels, International Normalized Ratio (INR) for prothrombin time, and etiology of liver disease. The model's validity was tested in 4 independent data sets, including (1) patients hospitalized for hepatic decompensation (referred to as {"}hospitalized{"} patients), (2) ambulatory patients with noncholestatic cirrhosis, (3) patients with primary biliary cirrhosis (PBC), and (4) unselected patients from the 1980s with cirrhosis (referred to as {"}historical{"} patients). In these patients, the model's ability to classify patients according to their risk of death was examined using the concordance (c)-statistic. The MELD scale performed well in predicting death within 3 months with a c-statistic of (1) 0.87 for hospitalized patients, (2) 0.80 for noncholestatic ambulatory patients, (3) 0.87 for PBC patients, and (4) 0.78 for historical cirrhotic patients. Individual complications of portal hypertension had minimal impact on the model's prediction (range of improvement in c-statistic: <.01 for spontaneous bacterial peritonitis and variceal hemorrhage to ascites: 0.01-0.03). The MELD scale is a reliable measure of mortality risk in patients with end-stage liver disease and suitable for use as a disease severity index to determine organ allocation priorities.",
author = "Kamath, {Patrick Sequeira} and Wiesner, {R. H.} and M. Malinchoc and Kremers, {Walter K} and Therneau, {Terry M} and Kosberg, {C. L.} and G. D'Amico and Dickson, {E. R.} and Kim, {W. R.}",
year = "2001",
doi = "10.1053/jhep.2001.22172",
language = "English (US)",
volume = "33",
pages = "464--470",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - A model to predict survival in patients with end-stage liver disease

AU - Kamath, Patrick Sequeira

AU - Wiesner, R. H.

AU - Malinchoc, M.

AU - Kremers, Walter K

AU - Therneau, Terry M

AU - Kosberg, C. L.

AU - D'Amico, G.

AU - Dickson, E. R.

AU - Kim, W. R.

PY - 2001

Y1 - 2001

N2 - A recent mandate emphasizes severity of liver disease to determine priorities in allocating organs for liver transplantation and necessitates a disease severity index based on generalizable, verifiable, and easily obtained variables. The aim of the study was to examine the generalizability of a model previously created to estimate survival of patients undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure in patient groups with a broader range of disease severity and etiology. The Model for End-Stage Liver Disease (MELD) consists of serum bilirubin and creatinine levels, International Normalized Ratio (INR) for prothrombin time, and etiology of liver disease. The model's validity was tested in 4 independent data sets, including (1) patients hospitalized for hepatic decompensation (referred to as "hospitalized" patients), (2) ambulatory patients with noncholestatic cirrhosis, (3) patients with primary biliary cirrhosis (PBC), and (4) unselected patients from the 1980s with cirrhosis (referred to as "historical" patients). In these patients, the model's ability to classify patients according to their risk of death was examined using the concordance (c)-statistic. The MELD scale performed well in predicting death within 3 months with a c-statistic of (1) 0.87 for hospitalized patients, (2) 0.80 for noncholestatic ambulatory patients, (3) 0.87 for PBC patients, and (4) 0.78 for historical cirrhotic patients. Individual complications of portal hypertension had minimal impact on the model's prediction (range of improvement in c-statistic: <.01 for spontaneous bacterial peritonitis and variceal hemorrhage to ascites: 0.01-0.03). The MELD scale is a reliable measure of mortality risk in patients with end-stage liver disease and suitable for use as a disease severity index to determine organ allocation priorities.

AB - A recent mandate emphasizes severity of liver disease to determine priorities in allocating organs for liver transplantation and necessitates a disease severity index based on generalizable, verifiable, and easily obtained variables. The aim of the study was to examine the generalizability of a model previously created to estimate survival of patients undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure in patient groups with a broader range of disease severity and etiology. The Model for End-Stage Liver Disease (MELD) consists of serum bilirubin and creatinine levels, International Normalized Ratio (INR) for prothrombin time, and etiology of liver disease. The model's validity was tested in 4 independent data sets, including (1) patients hospitalized for hepatic decompensation (referred to as "hospitalized" patients), (2) ambulatory patients with noncholestatic cirrhosis, (3) patients with primary biliary cirrhosis (PBC), and (4) unselected patients from the 1980s with cirrhosis (referred to as "historical" patients). In these patients, the model's ability to classify patients according to their risk of death was examined using the concordance (c)-statistic. The MELD scale performed well in predicting death within 3 months with a c-statistic of (1) 0.87 for hospitalized patients, (2) 0.80 for noncholestatic ambulatory patients, (3) 0.87 for PBC patients, and (4) 0.78 for historical cirrhotic patients. Individual complications of portal hypertension had minimal impact on the model's prediction (range of improvement in c-statistic: <.01 for spontaneous bacterial peritonitis and variceal hemorrhage to ascites: 0.01-0.03). The MELD scale is a reliable measure of mortality risk in patients with end-stage liver disease and suitable for use as a disease severity index to determine organ allocation priorities.

UR - http://www.scopus.com/inward/record.url?scp=0035146422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035146422&partnerID=8YFLogxK

U2 - 10.1053/jhep.2001.22172

DO - 10.1053/jhep.2001.22172

M3 - Article

C2 - 11172350

AN - SCOPUS:0035146422

VL - 33

SP - 464

EP - 470

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -